At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to see if Tec-RVd after 3 treatment cycles of Dara-RVd is safe for people with multiple myeloma. The people in this study have newly diagnosed multiple myeloma.
-
The standard approach to controlling pain after mastectomy includes intravenous and oral pain-relieving medications. In this study, researchers are determining if adding a long-acting local anesthetic, bupivacaine, into the wound at the end of the operation is more effective at reducing pain than the standard medications alone for women having a mastectomy on one side with no immediate reconstruction afterward.
-
KIF5B/RET is an abnormal gene that leads to the growth of lung cancer cells. Cabozantinib inhibits the effects of this gene. In addition, this drug interferes with other pathways that also cause cancer cells to grow, form new blood vessels, and spread to other parts of the body.
-
Studies have shown that patients with newly diagnosed localized non-germinomatous germ cell tumors (NGGCT) of the brain or spinal cord whose disease responds well to chemotherapy before receiving radiation therapy are more likely to be free of the disease for a longer time than patients in whom chemotherapy is less effective.
-
Researchers are assessing a lower dose of standard radiation therapy after chemotherapy in young people with germinomas. The patients in this study have germinomas of the central nervous system (brain or spinal cord).  It is hoped that this new approach can destroy germinomas with fewer long-term side effects.
- A Phase 1/2 Study of CBL0137 to Treat Advanced Solid Tumors in Children and Young Adults
Full Title A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma (PEPN2111) (CIRB)
Purpose
Researchers in this study are seeking the best dose of CBL0137 in people with solid tumors. They also want to see how well it works against certain cancers.
The best dose was already found in the first part of this study. The people in this study will now be limited to children and young adults with osteosarcoma or certain types of brain or brain stem tumors (gliomas). In addition, their cancers came back or keep growing even with treatment.
CBL0137 blocks signals between molecules inside a cell. Blocking these signals may kill cancer cells. CBL0137 is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You or your child must:
- Have osteosarcoma or a brain or brain stem glioma that keeps growing even with treatment.
- Have recovered from the serious side effects of prior therapies before getting CBL0137.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be between the ages of 1 and 30 years.
Contact
For more information or to see if you or your child can join this study, please call 833-MSK-KIDS.
Protocol
23-215Phase
Phase I/II (phases 1 and 2 combined)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04870944ClinicalTrials.gov
-
Researchers want to see if elacestrant alone or with abemaciclib works well against endometrial cancer. The people in this study have endometrial cancer that has spread or come back. Their cancers have a protein called the estrogen receptor (ER) and they have a normal version of the p53 gene. This gene stops cancer from growing.
- A Study of Acupuncture for Young Adults Who Stopped Getting Periods After Chemotherapy
Full Title Acupuncture for Adolescent and Young Adult Cancer Patients: (AcuAYA)
Purpose
Many people who get chemotherapy experience a loss of their period (amenorrhea). They may have menopause-like symptoms such as insomnia, hot flashes, and anxiety. The condition also increases the risk of infertility.
There is no treatment for period loss in people getting chemotherapy for cancer. Researchers are assessing acupuncture to treat amenorrhea caused by chemotherapy in young adults with cancer.
Acupuncture is a medical technique that involves the insertion of very thin needles into specific areas on the body. The goal is to promote health and well-being. Studies have shown that acupuncture may help recover the function of the ovaries and balance sex hormone levels.
If you join this study, you will be randomly assigned to one of these groups:
- The acupuncture group, who will have 12 acupuncture treatments over 12 weeks.
- The control group, who will be put on a waitlist. They will be able to have the same acupuncture treatment as the acupuncture group after a 16-week waiting period.
Who Can Join
To join this study, there are a few conditions. You must:
- Be English-speaking and under age 40.
- Had stage 1, 2, or 3 cancer diagnosed between the ages of 18 and 39.
- Had been having regular periods at the time of your cancer diagnosis.
- Have completed chemotherapy within the past year.
- Have not had a period for at least 3 months after finishing chemotherapy.
Contact
For more information about this study, please contact the Clinical Research Coordinator at [email protected] or 646-449-1074.
Protocol
25-020Phase
Phase II (phase 2)Investigator
Co-Investigators
Xiaotong LiDiseases
Locations
ClinicalTrials.gov ID
NCT06915116ClinicalTrials.gov
- A Phase 1-2 Study of Petosemtamab Alone or With Standard Chemotherapy in People With Advanced Colorectal Cancer
Full Title Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid tumors
Purpose
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
Petosemtamab is a bispecific antibody. It works against cancer by binding to two proteins. One protein is on cancer cells. The other protein is on intestinal stem cells, which help renew the lining of the intestines. Intestinal cancer stem cells may help cancer cells survive therapy. Petosemtamab is also designed to help your immune system kill cancer cells.
If you join this study, you will get petosemtamab alone or with standard chemotherapy. The standard chemotherapy will be either FOLFOX (5-fluorouracil [5-FU], leucovorin, and oxaliplatin) or FOLFIRI (5-FU, leucovorin, and irinotecan). All of the medications in this study are given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have inoperable or metastatic colorectal cancer with normal KRAS, NRAS, and BRAF genes.
- Have recovered from the serious side effects of previous treatments before getting the study therapy.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Rona Yaeger’s office at 646-888-5109.
Protocol
25-175Phase
Phase I/II (phases 1 and 2 combined)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT03526835ClinicalTrials.gov
-
In this study, researchers are assessing the safety and effectiveness of giving the drug disitamab vedotin alone and in combination with pembrolizumab immunotherapy in people with inoperable or metastatic urothelial cancers that make too much of the HER2 protein. Disitamab vedotin targets and kills cancer cells with the HER2 protein. Pembrolizumab boosts the power of the immune system to detect and destroy cancer cells.